The company’s revenues increased 19 percent, ahead of Zacks Consensus estimate. Zacks maintains a neutral rating for AmSurg stock.
At the end of December 2012, the company operated 250 ASCs. Of AmSurg’s centers, 149 perform GI procedures, 48 are multispecialty centers, 36 perform ophthalmology procedures and seven perform orthopedic procedures.
More Articles on Transactions and Valuation Issues:
13 Ambulatory Surgery Center Openings, Plans & Expansions
9 Statistics on Surgery Center Liquidity Based on Case Volume
ASC Sector M&A Activity: Outlook for 2014
